Effects of Dexmedetomidine and Dopamine on Renal Function After Selective Major Surgery in Adult Patients
| Registry | NCT03170739 |
|---|---|
| Status | Unknown |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: double, prevention |
| Enrollment | 180 (Estimated) |
| Sponsor | Tao Zhang (Other) |
| Conditions | Renal Function |
| Interventions | Dexmedetomidine, Dopamine (Drug) |
| Dates | start 2017-06-06, primary completion 2019-10-01 (estimated), completion 2019-12-01 (estimated), first posted 2017-05-31, last updated 2018-06-12 |
| Locations | 1 site in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Renal Function All trials of Dexmedetomidine All trials of Dopamine
Acute kidney injury (AKI) is associated with complications that may lead to multiorgan dysfunction and potentially to multi-organ failure after major surgery. Dexmedetomidine is a highly selective alpha(2)-adreno receptor agonist widely used during anesthesia. In animals, dexmedetomidine has shown protective effects in AKI after surgery. Dopamine (DA) is an organic chemical of the catecholamine and phenethylamine families that has been widely used to increased renal blood flow and urine output during surgery. However, the clinical effects of dexmedetomidine and dopamine on renal function are still controversial. The aim of this study is to investigate whether dexmedetomidine and dopamine have positive effects on renal function after selective major surgery.
Acute kidney injury (AKI) is associated with complications that may lead to multiorgan dysfunction and potentially to multi-organ failure in critically ill patients. AKI accounts for 5-10% after general surgery to 45% after cardiac surgery during hospital stays and tends to be associated with increased length of hospital stay as well as increased morbidity and mortality. Even slight increases in postoperative serum creatinine concentrations have been associated with almost 5-fold increases in mortality. Dexmedetomidine is a potent and highly selective alpha(2)-adreno receptor agonist that has analgesic, sedative, anxiolytic, and sympatholytic effects. In animals, dexmedetomidine has shown protective effects in several models of ischemia-reperfusion, which is thought to be the principal mechanism of AKI in the context of surgery. Dopamine (DA) is an organic chemical of the catecholamine and phenethylamine families that has been widely used to increased renal blood flow and urine output. However, the clinical effects of dexmedetomidine and dopamine on renal function are still controversial. The aim of this study is to investigate whether dexmedetomidine and dopamine have positive effects on renal function after selective major surgery.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Dexmedetomidine | Experimental | Drug: Dexmedetomidine | Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery. |
| Dopamine | Experimental | Drug: Dopamine | Dopamine 3ug/kg/min ivpump at the beginning of surgery. |
| Dexmedetomidine+dopamine | Experimental | Drug: Dexmedetomidine; Drug: Dopamine | Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery. |
| Control group | No intervention | No intervention |
Sex: All, ages: 18 Years to 80 Years
Inclusion Criteria: * Patients undergoing selective major surgery Exclusion Criteria: * Patients undergoing urologic surgery or neurosurgery * Patients with preoperative renal disorder
| Facility | City | Country | Status |
|---|---|---|---|
| First Affiliated Hospital, Sun Yat-sen University | Guangzhou | China | Recruiting |